Processing

Please wait...

Settings

Settings

Goto Application

1. WO2007141046 - METHOD FOR IDENTIFYING GENETIC MARKERS FOR SECONDARY TUMORS AND MEANS FOR THE IDENTIFICATION, LABELLING AND TARGETING OF SECONDARY TUMORS

Publication Number WO/2007/141046
Publication Date 13.12.2007
International Application No. PCT/EP2007/005138
International Filing Date 04.06.2007
IPC
C12Q 1/68 2006.01
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
68involving nucleic acids
CPC
C12Q 1/6886
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms
68involving nucleic acids
6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
6883for diseases caused by alterations of genetic material
6886for cancer
C12Q 2600/16
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS
2600Oligonucleotides characterized by their use
16Primer sets for multiplex assays
Applicants
  • FRAUNHOFER GESELLSCHAFT ZUR FÖRDERUNG DER ANGEWANDTEN FORSCHUNG E. V. [DE]/[DE] (AllExceptUS)
  • BORLAK, Jürgen [DE]/[DE] (UsOnly)
  • LEHNER, Frank [DE]/[DE] (UsOnly)
  • KLEMPNAUER, Jürgen [DE]/[DE] (UsOnly)
Inventors
  • BORLAK, Jürgen
  • LEHNER, Frank
  • KLEMPNAUER, Jürgen
Agents
  • BAUMBACH, F.
Priority Data
06090096.602.06.2006EP
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) METHOD FOR IDENTIFYING GENETIC MARKERS FOR SECONDARY TUMORS AND MEANS FOR THE IDENTIFICATION, LABELLING AND TARGETING OF SECONDARY TUMORS
(FR) procédé d'identification de cibles thérapeutiques dans des tumeurs secondaires, son emploi et moyens d'identification, de marquage et de ciblage de tumeurs secondaires
Abstract
(EN)
In comparison with primary tumors, where the organ by itself is the starting point of the malignant degeneration, metastases inherit a different emergence. The molecular causes leading to secondary liver malignancies are unknown so far. The aim of the present invention is therefore to make available an easy and efficient method for identifying therapeutical targets in secondary tumors, the use of novel therapeutical targets identified by the method for screening and determiningbeneficial means and/or drugs, and means and drugs for identifying, labeling and treating secondary metastases in the liver made up of or derived from tumor cells of the colon. In principle, expression of transcription factors is studied in the primary tumor, the secondary tumor and in the healthy organ, wherein the secondary tumor is formed, according to the invention, in particular of transcription factors being enriched in the healthy tissue of the organ, wherein the secondary tumor is formed, e.g. expression of liver enriched transcription factors HNF6 and/or Foxa2 or of NGN3, HSP105B, HSP10, HNF1 β, C/EBP is studied, such as by reverse transcription polymerase chain reaction, by gene chip analysis, by Western blotting technique, by studying the DNA binding of liver enriched transcription factors by electromobility shift assay (EMSA) or by genomic sequencing of therapeutical targets, such as of HNF6.
(FR)
L'émergence des métastases diffère de celle des tumeurs primaires pour lesquelles l'organe lui-même constitue le point de départ de la dégénérescence maligne. Les causes moléculaires de tumeurs malignes du foie secondaires sont encore inconnues. Par conséquent, la présente invention a pour objet un procédé simple et efficace d'identification de cibles thérapeutiques dans des tumeurs secondaires, l'utilisation des nouvelles cibles thérapeutiques identifiées par le procédé pour le criblage et la détermination de moyens et/ou de médicaments bénéfiques et des moyens et médicaments permettant l'identification, le marquage et le traitement de métastases secondaires dans le foie, composées de ou dérivées de cellules tumorales du côlon. En principe, l'expression des facteurs de transcription est étudiée dans la tumeur primaire, la tumeur secondaire et l'organe sain dans lequel la tumeur secondaire se forme; dans le cadre de la présente invention, le cas particulier de facteurs de transcription enrichis dans le tissu sain de l'organe dans lequel la tumeur secondaire se forme, p. ex. l'expression des facteurs de transcription enrichis du foie HNF6 et/ou Foxa2 ou de NGN3, HSP105B, HSP10, HNF1 β, C/EBP, est étudié, notamment par réaction en chaîne de polymérase par transcription inverse, par analyse de puce à ADN, par la technique du western blot, par l'étude du pouvoir liant d'ADN des facteurs de transcription enrichis du foie par electromobility shift assay (EMSA) ou par séquençage génomique de cibles thérapeutiques telles que HNF6.
Also published as
Latest bibliographic data on file with the International Bureau